Practice ProjectsDrug-Induced Xerostomia in Hemodialysis Patients and Its Implications in Oral HealthTorres, Roxana MHSN, RDN, LDN; Brunetti, Luigi PharmD, MPH; Morrow, Ellis MS, RDN, CSD, LD; Ziegler, Jane DCN, RDN, LDNAuthor Information Graduate Programs in Clinical Nutrition, Department of Nutritional Sciences, School of Health Related Professions, Rutgers, The State University of New Jersey, Newark. Correspondence: Roxana Torres MHSN, RDN, LDN, Graduate Programs in Clinical Nutrition, Department of Nutritional Sciences, School of Health Related Professions, Rutgers, The State University of New Jersey, 65 Bergen St 157, Newark, NJ 07107 ([email protected]). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Topics in Clinical Nutrition: October/December 2017 - Volume 32 - Issue 4 - p 340-349 doi: 10.1097/TIN.0000000000000119 Buy Metrics Abstract Xerostomia or dry mouth occurs when there is decreased production of saliva. This condition can lead to oral health complications (eg, dental caries, oral lesions), chewing and swallowing problems, and reduced quality of life. Hemodialysis patients are at increased risk of developing xerostomia because of polypharmacy, fluid restriction, salivary gland dysfunction, oral breathing, and systemic diseases. Drug-induced xerostomia increases the risk of oral diseases in these patients. The health care team needs to assess the symptoms of xerostomia in the hemodialysis population and to apply the latest recommendations for its management. This article describes the risks of drug-induced xerostomia in oral health and its management in patients on HD. © 2017 Wolters Kluwer Health, Inc. All rights reserved.